175 related articles for article (PubMed ID: 30301506)
1. SMAR1 promotes immune escape of Tri-negative Breast Cancer through a mechanism involving T-bet/PD-1 Axis.
Xiaohua W; Hongxia X; Rong D; Pingping W; Xing H; Yichao Z; Cheng C
Cell Mol Biol (Noisy-le-grand); 2018 Sep; 64(12):70-75. PubMed ID: 30301506
[TBL] [Abstract][Full Text] [Related]
2. miR-149-3p reverses CD8
Zhang M; Gao D; Shi Y; Wang Y; Joshi R; Yu Q; Liu D; Alotaibi F; Zhang Y; Wang H; Li Q; Zhang ZX; Koropatnick J; Min W
Open Biol; 2019 Oct; 9(10):190061. PubMed ID: 31594465
[TBL] [Abstract][Full Text] [Related]
3. IL-12 Influence mTOR to Modulate CD8
Wang H; Li J; Han Q; Yang F; Xiao Y; Xiao M; Xu Y; Su L; Cui N; Liu D
Int J Med Sci; 2017; 14(10):977-983. PubMed ID: 28924369
[No Abstract] [Full Text] [Related]
4. Nuclear Aurora kinase A triggers programmed death-ligand 1-mediated immune suppression by activating MYC transcription in triple-negative breast cancer.
Sun S; Zhou W; Li X; Peng F; Yan M; Zhan Y; An F; Li X; Liu Y; Liu Q; Piao H
Cancer Commun (Lond); 2021 Sep; 41(9):851-866. PubMed ID: 34251762
[TBL] [Abstract][Full Text] [Related]
5. T-bet expression in CD8+ T cells associated with chronic hepatitis B virus infection.
Fan R; Lan Y; Chen J; Huang Y; Yan Q; Jiang L; Song S; Li Y
Virol J; 2016 Jan; 13():14. PubMed ID: 26809262
[TBL] [Abstract][Full Text] [Related]
6. Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8(+) Cytolytic T Cell Responses.
Taylor A; Harker JA; Chanthong K; Stevenson PG; Zuniga EI; Rudd CE
Immunity; 2016 Feb; 44(2):274-86. PubMed ID: 26885856
[TBL] [Abstract][Full Text] [Related]
7. Tumoral PD-1hiCD8+ T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer.
Guo L; Cao C; Goswami S; Huang X; Ma L; Guo Y; Yang B; Li T; Chi Y; Zhang X; Wu J
Clin Sci (Lond); 2020 Apr; 134(7):711-726. PubMed ID: 32202617
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC.
Brockwell NK; Owen KL; Zanker D; Spurling A; Rautela J; Duivenvoorden HM; Baschuk N; Caramia F; Loi S; Darcy PK; Lim E; Parker BS
Cancer Immunol Res; 2017 Oct; 5(10):871-884. PubMed ID: 28848054
[TBL] [Abstract][Full Text] [Related]
9. Artemisinin enhances the anti-tumor immune response in 4T1 breast cancer cells in vitro and in vivo.
Cao Y; Feng YH; Gao LW; Li XY; Jin QX; Wang YY; Xu YY; Jin F; Lu SL; Wei MJ
Int Immunopharmacol; 2019 May; 70():110-116. PubMed ID: 30798159
[TBL] [Abstract][Full Text] [Related]
10. Constitutive expression of SMAR1 confers susceptibility to Mycobacterium tuberculosis infection in a transgenic mouse model.
Yadav B; Malonia SK; Majumdar SS; Gupta P; Wadhwa N; Badhwar A; Gupta UD; Katoch VM; Chattopadhyay S
Indian J Med Res; 2015 Dec; 142(6):732-41. PubMed ID: 26831422
[TBL] [Abstract][Full Text] [Related]
11. Silencing of COL3A1 represses proliferation, migration, invasion, and immune escape of triple negative breast cancer cells via down-regulating PD-L1 expression.
Yang F; Lin L; Li X; Wen R; Zhang X
Cell Biol Int; 2022 Nov; 46(11):1959-1969. PubMed ID: 35930601
[TBL] [Abstract][Full Text] [Related]
12. Regulation of T cell lineage commitment by SMAR1 during inflammatory & autoimmune diseases.
Mirlekar B; Majumdar S; Khetmalas M; Chattopadhyay S
Indian J Med Res; 2015 Oct; 142(4):405-13. PubMed ID: 26609032
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
14. [The effects of imiquimod on an animal model of asthma].
Yin KS; Jin SX; Bian T; Wu QZ; Wang X; Yao X
Zhonghua Jie He He Hu Xi Za Zhi; 2007 Jul; 30(7):509-17. PubMed ID: 17961405
[TBL] [Abstract][Full Text] [Related]
15. CD8+ T cells undergo activation and programmed death-1 repression in the liver of aged Ae2a,b-/- mice favoring autoimmune cholangitis.
Concepcion AR; Salas JT; Sáez E; Sarvide S; Ferrer A; Portu A; Uriarte I; Hervás-Stubbs S; Oude Elferink RP; Prieto J; Medina JF
Oncotarget; 2015 Oct; 6(30):28588-606. PubMed ID: 26396175
[TBL] [Abstract][Full Text] [Related]
16.
Bhattacharya A; Mukherjee S; Khan P; Banerjee S; Dutta A; Banerjee N; Sengupta D; Basak U; Chakraborty S; Dutta A; Chattopadhyay S; Jana K; Sarkar DK; Chatterjee S; Das T
Sci Signal; 2020 Oct; 13(654):. PubMed ID: 33082288
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 17A promotes cell migration, enhances anoikis resistance, and creates a microenvironment suitable for triple negative breast cancer tumor metastasis.
Tsai YF; Huang CC; Lin YS; Hsu CY; Huang CP; Liu CY; Chiu JH; Tseng LM
Cancer Immunol Immunother; 2021 Aug; 70(8):2339-2351. PubMed ID: 33512556
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol attenuates TNBC lung metastasis by down-regulating PD-1 expression on pulmonary T cells and converting macrophages to M1 phenotype in a murine tumor model.
Han X; Zhao N; Zhu W; Wang J; Liu B; Teng Y
Cell Immunol; 2021 Oct; 368():104423. PubMed ID: 34399171
[TBL] [Abstract][Full Text] [Related]
19. Progression of autoimmune hepatitis is mediated by IL-18-producing dendritic cells and hepatic CXCL9 expression in mice.
Ikeda A; Aoki N; Kido M; Iwamoto S; Nishiura H; Maruoka R; Chiba T; Watanabe N
Hepatology; 2014 Jul; 60(1):224-36. PubMed ID: 24700550
[TBL] [Abstract][Full Text] [Related]
20. Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer: A pre-clinical study in a murine model.
Zhu J; Yu M; Chen L; Kong P; Li L; Ma G; Ge H; Cui Y; Li Z; Pan H; Xie H; Zhou W; Wang S
Diagn Interv Imaging; 2018 Mar; 99(3):135-142. PubMed ID: 29398572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
